RECOMMEND platform testing interventions for adults receiving ECMO
Official title: Generating New Evidence to Reduce Major Complications to Improve the Safety and Efficacy of ECMO in Severe Cardiac and Respiratory Failure (RECOMMEND)
Run by Australian and New Zealand Intensive Care Research Centre · NCT06526533 · Data updated 2026-11-12
This platform tests whether different treatments, such as liberal versus restrictive red blood cell transfusion strategies, help adults on ECMO survive and need less organ support and hospital resources by day 28.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | Australian and New Zealand Intensive Care Research Centre Academic / other |
| Locations | 3 sites (Camperdown, New South Wales and 2 other locations) |
| Status | Recruiting |
| Started | March 23, 2026 |
| Main results expected | June 2028 |
| Study ends | June 2029 |
| Registry record updated | May 13, 2026 |
| Trial ID | NCT06526533 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) receiving ECMO at a participating Australian ICU who are enrolled in the EXCEL registry and meet the domain-specific inclusion criteria are eligible.
✕Probably not a fit
Patients with imminent, unavoidable death, those with contraindications to a domain intervention (for example refusal of blood transfusion), or those expected to cease ECMO within 24 hours are unlikely to benefit from enrollment.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
RECOMMEND is an investigator-initiated, multicentre, open-label randomized adaptive platform conducted in Australian ICUs using Bayesian logic to compare multiple interventions for adults receiving ECMO. Participants are enrolled via the national EXCEL registry and allocated within domain structures to receive interventions either simultaneously or sequentially, with primary outcomes of survival, organ support and resource use to day 28. One core domain compares liberal versus restrictive red blood cell transfusion thresholds, and additional domains can be added or stopped based on adaptive analyses. The design aims to efficiently identify effective, safe, and cost-effective strategies for this high-risk, resource-intensive population.
Why it matters
Potential benefit: If successful, the platform could identify treatments that increase survival, shorten time on organ support, and reduce ICU costs for people receiving ECMO.
How similar studies have gone: Adaptive platform trials and transfusion-threshold trials in critical care have produced useful results, but an adaptive platform focused specifically on ECMO patients is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
PLATFORM INCLUSION CRITERIA: * Patients receiving ECMO * Patients enrolled in the EXCEL Registry - NCT03793257 PLATFORM EXCLUSION CRITERIA: * Treating clinician regards death as imminent and inevitable * Treating clinician determines it is not in the patient's best interests RBC TRANSFUSION DOMAIN INCLUSION CRITERIA: • Aged 18 years or older RBC TRANSFUSION DOMAIN EXCLUSION CRITERIA: * Contraindication to RBC transfusion (including known patient preference) * Limitations of care put in place either through patient wishes or the treating medical teams. * Participant has already received ECMO \>12 hours. The start of ECMO is defined as the time of initiation of extracorporeal blood flow unless ECMO was initiated during a surgical intervention in which case the start of ECMO is defined as the arrival time into the initial ICU (post-surgery) * The treating physician anticipates that ECMO treatment will cease before the end of tomorrow * The treating physician deems the study is not in the patient's best interest * The treating physician has concern regarding patient ability to tolerate restrictive or liberal transfusion trigger thresholds * Actively listed for a solid organ transplant and has not yet received one * Suspected or confirmed to be pregnant * Previous ECMO treatment during the same hospital admission
Where it's running
-
St. Vincent's Hospital Sydney
Sydney, New South Wales, Australia Recruiting -
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia Not yet recruiting -
The Alfred Hospital
Melbourne, Victoria, Australia Not yet recruiting
Study contacts
- Study coordinator: Curtis Hopkins, B.BioMed, MPH, MHA
- Email: curtis.hopkins@monash.edu
- Phone: +61 3 9903 0343
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Real-time, algorithm-driven ventilation feedback to improve lung protection in ARDS
This study tests whether a cloud-based, real-time ventilation feedback system helps doctors deliver more lung-protective ventilation to adults with ARDS on invasive mechanical ventilation.
-
VoiceLove app to improve communication, family engagement, and delirium in critically ill adults
This trial will test whether the VoiceLove phone app helps families communicate with intubated adults in the medical or coronary ICU and whether it improves family engagement and reduces ICU delirium.
-
Predicting Extubation Problems With Machine Learning
This study tests whether computer models can predict extubation failure in adults on ventilators in the ICU.
-
Levetiracetam Dosing in Critically Ill on CRRT
This study tests how levetiracetam behaves in the bodies of adults on continuous renal replacement therapy to help figure out the best dosing.
-
Smartphone-based EEG to detect hidden awareness in ICU patients with brain injuries
Researchers will test a smartphone-enabled EEG to see if it can reveal Cognitive Motor Dissociation in ICU patients who can’t show commands at bedside.
-
Respiratory Physiotherapy in Critically Ill Pneumonia Patients
This study tests whether a structured breathing and chest therapy program can change inflammatory biomarkers in adults with pneumonia in the ICU compared to usual care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.